Ioannis Charalampopoulos | Neuroscience | Best Researcher Award

Prof. Ioannis Charalampopoulos
| Neuroscience | Best Researcher Award 🏆

Professor of Pharmacology at Medical School, University of Crete,Greece🎓

Dr. Ioannis Charalampopoulos is a distinguished Professor of Pharmacology at the University of Crete’s Medical School and a Group Leader at the Institute of Molecular Biology and Biotechnology (IMBB), Foundation of Research and Technology, Hellas (FORTH). With a focus on neuropharmacology and molecular biology, his research has contributed significantly to the study of neurodegenerative diseases, brain development, and regeneration. He has an extensive academic and research career spanning over two decades, with notable achievements in the development of novel therapeutic strategies for Alzheimer’s and spinal cord injury.

 

Professional Profile 

Education 🎓:

  • 2021-present: Director of the Graduate Program in Neurosciences, Medical School, University of Crete
  • 2010-2023: Lecturer, Assistant and Associate Professor of Pharmacology, Medical School, University of Crete
  • 2007-2010: Researcher, Medical School, University of Crete
  • 2005-2007: Post-doctoral Fellow, Molecular Neurobiology Lab, Karolinska Institutet, Sweden
  • 2001-2005: PhD in Pharmacology, Medical School, University of Crete
  • 1998-2000: Master of Science in Neurosciences, Medical School, University of Crete
  • 1990-1996: BSc, Department of Biology, University of Patras

Work Experience 💼:

  • 2023-present: Professor of Pharmacology, Medical School, University of Crete
  • 2018-present: Researcher/Group Leader, Institute of Molecular Biology and Biotechnology (IMBB), FORTH
  • 2021-present: Director, Graduate Program in Neurosciences, Medical School, University of Crete
  • 2010-2023: Lecturer, Assistant and Associate Professor of Pharmacology, University of Crete
  • 2007-2010: Researcher, Medical School, University of Crete
  • 2005-2007: Post-doctoral Fellow, Molecular Neurobiology Lab, Karolinska Institutet, Sweden

Skills 🔍

Dr. Charalampopoulos is highly skilled in neuropharmacology, molecular biology techniques, and neurodegenerative disease research. His expertise includes:

  • Neurotrophin receptor structure-function analysis
  • Development of therapeutic ligands for brain regeneration
  • Neurogenesis and neuroprotection strategies
  • Animal models of Alzheimer’s disease and spinal cord injury
  • Human iPSC-derived neural platforms for disease modeling
  • Collaborative research in neuroscience and pharmacology

Awards and Honors 🏆

Dr. Charalampopoulos has received multiple recognitions throughout his career, including prestigious grants for his innovative work in neuroscience and neurodegenerative disease treatment:

  • HORIZON-EIC-2022 European Commission Grant: Coordinating a project on soft-robot-assisted therapeutic delivery for neurological disorders (budget: 2.9 million euros).
  • National Flagship Project: Funding for the elucidation of the genetic basis of Alzheimer’s and Parkinson’s diseases (budget: 610,000 euros).
  • Numerous research accolades, with over 80 publications in peer-reviewed journals (h-index: 35, citations >3000).

🤝 Memberships:

Dr. Charalampopoulos is a member of several prestigious scientific organizations, including:

  • International Society for Neuroscience
  • European Society of Neurochemistry
  • Society for Neuroscience (SfN)
  • Greek Society for Pharmacology

Teaching Experience 👩‍🏫:

Dr. Charalampopoulos has been actively involved in educating future generations of neuroscientists, particularly through his role as the Director of the Graduate Program in Neurosciences at the University of Crete. His teaching experience includes:

  • Undergraduate and postgraduate courses in pharmacology, neuropharmacology, and molecular biology.
  • Mentoring and supervising PhD students and postdoctoral researchers in pharmacology and neuroscience.
  • Developing innovative teaching methods, including the use of human stem cell models in neuroscience research.

Research Focus 🔬:

Dr. Charalampopoulos’ research interests revolve around the molecular mechanisms by which growth factors and their receptors regulate the regenerative capacity of the nervous system. Key areas include:

  • Neurotrophins: Their role in brain development, neurogenesis, neuronal survival, and repair during aging.
  • Neurodegenerative Diseases: Investigating novel therapeutic strategies for Alzheimer’s disease, Parkinson’s disease, and spinal cord injury.
  • Ligand Development: Creating novel ligands targeting neurotrophin receptors to enhance regenerative and neuroprotective effects.
  • Stem Cell Models: Using human induced pluripotent stem cell-derived platforms to test therapeutics for neurodegenerative diseases.
    His ultimate goal is to decipher the signaling mechanisms underlying neurodegeneration and regeneration, leading to the development of novel drugs for brain repair.
Conclusion 

Dr. Ioannis Charalampopoulos is undoubtedly a top contender for the Best Researcher Award. His exceptional contributions to neuroscience, his innovative approaches in neuropharmacology, and his ability to secure substantial research funding demonstrate that he is not only an accomplished researcher but also a transformative figure in the field of neurodegenerative diseases. His strengths lie in the originality of his work, leadership in research initiatives, and mentorship in education. With slight improvements in public outreach, collaborative networks, and clinical translation, he can further elevate his already remarkable career. Therefore, Dr. Charalampopoulos is a highly deserving nominee for the Best Researcher Award, given his outstanding scientific contributions, leadership, and lasting impact on the field of neuroscience.

📚 Publilcation

  • “Stimulating myelin restoration with BDNF: a promising therapeutic approach for Alzheimer’s disease”
    • Year: 2024
    • Journal: Frontiers in Cellular Neuroscience
    • Type: Review
    • DOI: 10.3389/fncel.2024.1422130
  • “Editorial: Steroid receptors in neuron and glia”
    • Year: 2024
    • Journal: Frontiers in Endocrinology
    • Type: Editorial
    • DOI: 10.3389/fendo.2024.1472908
  • “Comprehensive characterization of the neurogenic and neuroprotective action of a novel TrkB agonist using mouse and human stem cell models of Alzheimer’s disease”
    • Year: 2024
    • Journal: Stem Cell Research & Therapy
    • Type: Journal Article
    • DOI: 10.1186/s13287-024-03818-w
  • “Cover Image, Volume 72, Issue 4”
    • Year: 2024
    • Journal: Glia
    • Type: Journal Article
    • DOI: 10.1002/glia.24399
  • “Dynamics of myelin deficits in the 5xFAD mouse model for Alzheimer’s disease and the protective role of BDNF”
    • Year: 2024
    • Journal: Glia
    • Type: Journal Article
    • DOI: 10.1002/glia.24505
  • “Multimodal beneficial effects of BNN27, a Nerve Growth Factor synthetic mimetic, in the 5xFAD mouse model of Alzheimer’s Disease”
    • Year: 2024
    • Type: Preprint
    • DOI: 10.21203/rs.3.rs-3886007/v1
  • “Development of Pleiotropic TrkB and 5-HT<sub>4</sub> Receptor Ligands as Neuroprotective Agents”
    • Year: 2024
    • Journal: Molecules
    • Type: Journal Article
    • DOI: 10.3390/molecules29020515
  • “Butanolides and Butenolides from a Marine-Derived Streptomyces sp. Exert Neuroprotective Activity through Activation of the TrkB Neurotrophin Receptor”
    • Year: 2023
    • Journal: Marine Drugs
    • Type: Journal Article
    • DOI: 10.3390/md21090465
  • “Neurotrophin Analog ENT-A044 Activates the p75 Neurotrophin Receptor, Regulating Neuronal Survival in a Cell Context-Dependent Manner”
    • Year: 2023
    • Journal: International Journal of Molecular Sciences
    • Type: Journal Article
    • DOI: 10.3390/ijms241411683
  • “Neurotrophin Analog ENT-A044 Activates the p75 Neurotrophin Receptor Promoting Cell Death in Mouse and Human Neuronal Cells”
    • Year: 2023
    • Type: Preprint
    • DOI: 10.20944/preprints202306.1633.v1

Hilmar Bading | Neuroscience | Best Researcher Award

Prof Dr Hilmar Bading | Neuroscience | Best Researcher Award 

 Professor and Head of Department at Heidelberg University, Germany

 

Professor Dr. Hilmar Bading is a distinguished neurobiologist currently serving as a Professor and Chair of the Department of Neurobiology at Heidelberg University, Germany. He is also the Director of the Interdisciplinary Center for Neurosciences (IZN) at the same institution.

professional profile 

scopus

🎓 Education

Professor Bading completed his medical degree at Heidelberg University in 1984. He earned his doctorate (Dr. med.) under the supervision of Professor Wilhelm Hasselbach, with a focus on calcium transport ATPase in muscle at the Max-Planck-Institut für medizinische Forschung, Heidelberg.

💼 Work Experience

Professor Bading has an extensive academic and research career. He has held key positions including Group Leader at the MRC Laboratory of Molecular Biology in Cambridge, England (1993-2001), and postdoctoral fellowships at Harvard Medical School, USA, and the Max-Planck-Institut für molekulare Genetik, Berlin. Since 2001, he has led the Department of Neurobiology at Heidelberg University. Additionally, he is the scientific founder of FundaMental Pharma GmbH and the founder of the Hilmar Bading Stiftung BrainAid.

🔬 Research Focus

His research primarily revolves around the molecular mechanisms that regulate gene expression in neurons, particularly focusing on the role of nuclear calcium in neuroprotection and neurodegeneration. His groundbreaking work has significantly advanced our understanding of how synaptic activity influences gene expression in the nervous system.

🏆 Awards and Honors

Professor Bading’s contributions to science have been widely recognized. He has received several prestigious awards, including the Wolfgang-Paul-Prize from the Alexander von Humboldt-Foundation (2001), an ERC Advanced Grant (2008), and an ERC Proof-of-Concept Grant (2015). In 2019, he was elected as a member of the Leopoldina, the German National Academy of Sciences.

🏅 Memberships

He has been an active member of several prominent scientific boards and commissions, including the Scientific Advisory Board of the Spemann Graduate School of Biology and Medicine at the University of Freiburg, the Commission of the International Max-Planck Research Schools, and the Wellcome Trust Neuroscience Panel in London.

👨‍🏫 Teaching Experience

With a commitment to nurturing the next generation of scientists, Professor Bading has supervised over 25 PhD students as the principal supervisor and co-supervised an additional 50 PhD students. His dedication to teaching is also reflected in his guidance of approximately 80 Master’s and Bachelor’s theses over the past decade.

🔍 Skills

Professor Bading’s expertise lies in molecular biology, neurobiology, and the study of intracellular signaling pathways. His leadership in academia and industry highlights his ability to translate scientific discoveries into practical applications.

publications

  • Neuron–astrocyte metabolic coupling facilitates spinal plasticity and maintenance of inflammatory pain
    • Year: 2024
    • Journal: Nature Metabolism
    • Authors: Marty-Lombardi, S., Lu, S., Ambroziak, W., Fleming, T., Siemens, J.
    • Emoji: 🧠🔬💡
  • TwinF interface inhibitor FP802 stops loss of motor neurons and mitigates disease progression in a mouse model of ALS
    • Year: 2024
    • Journal: Cell Reports Medicine
    • Authors: Yan, J., Wang, Y.M., Hellwig, A., Bading, H.
    • Emoji: 🦠🧬🔬
  • Activin A targets extrasynaptic NMDA receptors to ameliorate neuronal and behavioral deficits in a mouse model of Huntington disease
    • Year: 2023
    • Journal: Neurobiology of Disease
    • Authors: Nassrallah, W.B., Ramandi, D., Cheng, J., Bading, H., Raymond, L.A.
    • Emoji: 🧠💉🧩
  • The Disruption of NMDAR/TRPM4 Death Signaling with TwinF Interface Inhibitors: A New Pharmacological Principle for Neuroprotection
    • Year: 2023
    • Journal: Pharmaceuticals
    • Authors: Yan, J., Bading, H.
    • Emoji: 💊🧬🔒
  • Expression of the primate-specific LINC00473 RNA in mouse neurons promotes excitability and CREB-regulated transcription
    • Year: 2023
    • Journal: Journal of Biological Chemistry
    • Authors: Pruunsild, P., Bengtson, C.P., Loss, I., Lohrer, B., Bading, H.
    • Emoji: 🧬🧠📈
  • Ryanodine Receptor Mediated Calcium Release Contributes to Ferroptosis Induced in Primary Hippocampal Neurons by GPX4 Inhibition
    • Year: 2023
    • Journal: Antioxidants
    • Authors: Gleitze, S., Ramírez, O.A., Vega-Vásquez, I., Paula-Lima, A., Hidalgo, C.
    • Emoji: 🧪🧬💥
  • Neuronal nuclear calcium signaling suppression of microglial reactivity is mediated by osteoprotegerin after traumatic brain injury
    • Year: 2022
    • Journal: Journal of Neuroinflammation
    • Authors: Fröhlich, A., Olde Heuvel, F., Rehman, R., Bading, H., Roselli, F.
    • Emoji: 🧠⚕️🔧
  • N-methyl-D-aspartate Receptor-mediated Preconditioning Mitigates Excitotoxicity in Human Induced Pluripotent Stem Cell-derived Brain Organoids
    • Year: 2022
    • Journal: Neuroscience
    • Authors: Bauersachs, H.G., Bengtson, C.P., Weiss, U., Pruunsild, P., Bading, H.
    • Emoji: 🧪🧠🌱
  • Dysregulation of Npas4 and Inhba expression and an altered excitation-inhibition balance are associated with cognitive deficits in DBA/2 mice
    • Year: 2022
    • Journal: Learning and Memory
    • Authors: Oberländer, K., Witte, V., Mallien, A.S., Bengtson, C.P., Bading, H.
    • Emoji: 🧠🧩📉
  • Disrupted expression of mitochondrial NCLX sensitizes neuroglial networks to excitotoxic stimuli and renders synaptic activity toxic
    • Year: 2022
    • Journal: Journal of Biological Chemistry
    • Authors: Hagenston, A.M., Yan, J., Bas-Orth, C., Sekler, I., Bading, H.
    • Emoji: 🧬⚠️🧠

 

Marjan Shariatpanahi | Neuroscience | Best Researcher Award

Dr Marjan Shariatpanahi |  Neuroscience | Best Researcher Award 

Associate professor at Iran university of medical sciences,Iran

Dr. Marjan Shariatpanahi is an Associate Professor in the Department of Pharmacology and Toxicology at the School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran. With extensive experience in toxicology and pharmacology, Dr. Shariatpanahi has made significant contributions to research on neurodegenerative diseases and toxicology.

professional profile

scopus

google scholar

Education 🎓

Dr. Shariatpanahi holds a Doctor of Pharmacy (Pharm. D.) from Islamic Azad University, Tehran (2000-2006) with a thesis on thymidine phosphorylase and estrogen receptor alpha in colorectal cancer. She also earned a Ph.D. in Toxicology from Tehran University of Medical Sciences (2009-2014), focusing on the effects of PKG on spatial memory deficits and markers of autophagy and apoptosis in rats.

Work Experience 🏥

Dr. Shariatpanahi has a diverse professional background. She has been the Head of the Pharmacology & Toxicology Department at Iran University of Medical Sciences since 2017. Her previous roles include Dean of the Educational Office (2020-2023), Head of Student and Cultural Affairs (2019-2020), and faculty member at the Neuroscience Research Center (2018-present). She has also worked as an Assistant Professor at both Iran University of Medical Sciences and Guilan University of Medical Sciences, and as a Responsible Pharmacist in various institutions.

Skills 🛠️

Dr. Shariatpanahi is proficient in various research techniques, including IHC, Western blot, ICC, in vivo studies, and behavioral tests for neurodegenerative diseases. Her expertise extends to TLC, spectrophotometry, SPSS, PRISM, ELISA, and gas chromatography. She is also skilled in using atomic absorption machines and Endnote.

Awards and Honors 🏅

Dr. Shariatpanahi has received several accolades, including being named the best professor at the Vosough Festival of IUMS (2023) and being recognized as a selected pharmacist (2022). She was also acknowledged as a top student in toxicology and pharmacy, receiving first ranks in board examinations and seminars.

Professional Memberships 🔗

Dr. Shariatpanahi is a member of the Iranian Association of Toxicology, the Iranian Medical Council, the Iranian Association of Pharmacists, the Iranian Probiotics Society, and the Talent Society of Tehran University.

Teaching Experience 📚

Dr. Shariatpanahi has taught a wide range of courses across various levels. For Ph.D. students, she covers basics of pharmacology. For Doctor of Pharmacy students, she teaches toxicology, pharmacology, clinical toxicology, and specialized pharmacy language. Her M.Sc. teaching includes environmental toxicology, forensic toxicology, and advanced research methods, while for B.Sc. students, she focuses on toxicology.

Research Focus 🔬

Dr. Shariatpanahi’s research interests include neuroscience, with a focus on autism, Alzheimer’s disease, memory, and Parkinson’s disease. She is also involved in toxicology, environmental toxicology, pharmacology, cell signaling, stem cell therapy, and the study of behavioral investigations on animals. Her work explores various markers and mechanisms in carcinogenesis, angiogenesis, and the protective and toxic effects of nanoparticles.

Conclusion

Dr. Marjan Shariatpanahi’s extensive qualifications, leadership roles, significant research contributions, and recognition in the field make him an excellent candidate for the Best Researcher Award. His achievements demonstrate a strong commitment to advancing knowledge in pharmacology and toxicology, contributing valuable insights into neurodegenerative diseases, toxicology, and pharmacology.

publication